Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases

Cancer

Volumn 113, Issue 5, 2008, Pages 936-944

  Zerilli, Monica ^a   Amato, Marco C ^a   Martorana, Anna ^a   Cabibi, Daniela ^a   Coy, Johannes F ^b   Cappello, Francesco ^a   Pompei, Giancarlo ^a   Russo, Antonio ^a   Giordano, Carla ^a   Rodolico, Vito ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b R Biopharm AG Rhome Ltd Scotland   (Germany)

Author keywords

Aerobic glycolysis; Lymph node metastases; Papillary thyroid carcinoma (PTC); Pentose phosphate pathway (PPP); Tranketolase like 1 (TKTL1)

Indexed keywords

ANTIBODY; RNA; TRANSKETOLASE; TKTL1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PAPILLARY CARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RNA ANALYSIS; SCLEROSIS; THYROID CARCINOMA; TUMOR VOLUME; ADOLESCENT; DISEASE COURSE; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; CARCINOMA, PAPILLARY; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; THYROID NEOPLASMS; TRANSKETOLASE;

EID: 52049110833     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23683     Document Type: Article

References (33)

1. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414-424.
2. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428.
3. Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R, Belfiore A. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab. 2004;89:3713-3720.
4. Rosen IB, Azadian A, Walfish PG, Salem S, Lansdown E, Bedard YC. Ultrasound-guided fine-needle aspiration biopsy in the management of thyroid disease. Am J Surg. 1993;166:346-349.
5. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1463.
6. Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5:43-63.
7. Jukkola A, Bloigu R, Ebeling T, Salmela P, Blanco G. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer. 2004;11:571-579.
8. Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph-node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90:5723-5729.
9. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab. 1997;82:3553-3562.
10. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 1981;70:511-518.
11. Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res. 2003;63:3847-3854.
12. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633-4646.
13. Warburg O. Uber den Stoffwechsel der Carcinomzelle. Naturwissenschaften. 1924;12:1131-1137.
14. Schenk G, Duggleby RG, Nixon PF. Properties and functions of the thiamin diphosphate dependent enzyme transketolase. Int J Biochem Cell Biol. 1998;30:1297-1318.
15. Coy JF, Dressler D, Wilde J, Schubert P. Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab. 2005;51:257-273.
16. Langbein S, Zerilli M, Zur Hausen A, et al. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer. 2006;94:578-585.
17. Coy JF, Dubel S, Kioschis P, et al. Molecular cloning of tissue-specific transcripts of a transketolase-related gene: implications for the evolution of new vertebrate genes. Genomics. 1996;32:309-316.
18. Cascante M, Centelles JJ, Veech RL, Lee WN, Boros LG. Role of thiamin (vitamin B-1) and transketolase in tumor cell proliferation. Nutr Cancer. 2000;36:150-154.
19. Foldi M, Stickeler E, Bau L, et al. Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. Oncol Rep. 2007;17:841-845.
20. Hu LH, Yang JH, Zhang DT, et al. The TKTL1 gene influences total transketolase activity and cell proliferation in human colon cancer LoVo cells. Anticancer Drugs. 2007;18:427-433.
21. Staiger WI, Coy JF, Grobholz R, et al. Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. Oncol Rep. 2006;16:657-661.
22. Volker HU, Scheich M, Schmausser B, Kammerer U, Eck M. Overexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomas. Eur Arch Otorhinolaryngol. 2007;264:1431-1436.
23. Zhang S, Yang JH, Guo CK, Cai PC. Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Lett. 2007;253:108-114.
24. Krockenberger M, Honig A, Rieger L, et al. Transketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastases. Int J Gynecol Cancer. 2007;17:101-106.
25. Boros LG, Puigjaner J, Cascante M, et al. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res. 1997;57:4242-4248.
26. Shah JP, Kian K, Forastiere A, et al. American Joint Committee on Cancer. Cancer Staging Manual. 6th edition. New York: Springer; 2002.
27. Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992;112:1139-1146
28. Baudin E, Travagli JP, Ropers J, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer. 1998;83:553-559.
29. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891-899.
30. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med. 2002;53:89-112.
31. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res. 2006;66:5216-5223.
32. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol. 2007;19:223-229.
33. Stephenson TJ. Papillary carcinoma of the thyroid: a tumour still with no benign neoplastic counterpart. Histopathology. 2001;39:536-538.